Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 592 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR No Survival Advantage from Radical Hysterectomy in Patients with Cervical Cancer... September 22, 2020 FDA Approves Relugolix for Advanced Prostate Cancer January 7, 2021 Can Eating Grilled or Charred Foods Cause Cancer? January 10, 2023 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Load more HOT NEWS Cancer in My Community: Expanding Genetic Testing in Thailand How to Stay Connected When Your Partner Has Cancer Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3...
